• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    9/29/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email

    Conference Call Scheduled for today, September 29, 2025, at 5:00pm ET

    Company introduces fiscal year 2026 Revenue and Adjusted EBITDA guidance

    Company appoints new Chief Operating Officer

    GARDNER, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year 2025 for the period ended June 30, 2025.

    Q4 2025 Financial Highlights (3 Months Ended June 30, 2025):

    • Revenue was $6.2 million, a new quarterly record, compared to $4.7 million in the same quarter of the previous fiscal year and compared to $4.2 million in the most recent sequential quarter, representing growth of approximately 48%.
    • Production revenue was $5.1 million compared to $2.8 million in the same quarter of the previous fiscal year and compared to $3.3 million in the most recent sequential quarter, representing growth of approximately 54%.
    • Engineering revenue was $1.1 million compared to $1.9 million in the same quarter of the previous fiscal year and compared to $0.9 million in the most recent sequential quarter.
    • Gross margins were 13.0% compared to 21.7% in the same quarter of the previous fiscal year and compared to 10.0% in the most recent sequential quarter.
    • Net loss for the quarter was $(1.4) million, compared to $(1.4) million in the same quarter of the previous fiscal year, and compared to $(2.1) million in the most recent sequential quarter.
    • Adjusted EBITDA was $(0.9) million for the quarter compared to $(1.1) million in the same quarter of the previous fiscal year and compared to $(1.3) million in the most recent sequential quarter.



    FY 2025 Financial Highlights (Year Ended June 30, 2025):

    • Revenue was $19.1 million compared to $19.1 million in the previous fiscal year.
    • Production revenue was $14.2 million compared to $10.6 million in the previous fiscal year, representing growth of approximately 34%. Engineering revenue was $4.9 million compared to $8.5 million in the previous fiscal year.
    • Gross margins were 17.8% compared to 30.3% in the previous fiscal year.
    • Net loss was ($5.8) million compared to $(3.0) million in the previous fiscal year.
    • Adjusted EBITDA was $(3.7) million compared to $(1.6) million in the previous fiscal year.



    FY 2026 Financial Guidance (Year Ended June 30, 2026):

    • The Company projects for the fiscal year 2026 revenue to be in excess of $25 million, which represents 31% growth over the Company's fiscal year 2025 revenue.
    • The Company expects fiscal year 2026 gross margin to be approximately 30%, an improvement compared to 18% in fiscal 2025.
    • The Company projects fiscal year 2026 Adjusted EBITDA be approximately $0.5 million compared to $(3.7) million in fiscal 2025.



    "During the fourth quarter, we reported quarterly revenue of $6.2 million, a new record for the Company and up 31% from the year ago quarter, as we executed against a strong order backlog driven by recent multi-year agreements with a top tier aerospace company and a surgical robotics company," commented Dr. Joe Forkey, CEO of Precision Optics. "The challenges we faced in getting production lines ramping to greater volumes had greater financial impact than anticipated. However, the underlying growth in the business is the source. Our two largest production customers are asking us to produce greater quantities, and we are working to add to our production capacity to meet demand. It is our current expectation that fiscal 2026 revenue will be approximately $25 million, which would equate to over 30% growth from fiscal 2025."

    "Margins were impacted by production yields, staffing and efficiency challenges along with unanticipated tariff costs. During the first quarter of Fiscal 2026 we renegotiated pricing agreements with one customer to account for some of the yield shortfalls, and we expect the impact of design revisions and related manufacturing improvements to be in place later this year. These improvements are expected to result in continued gross margin gains from quarter to quarter during Fiscal 2026. Finally, we are kicking off new product development engagements resulting from our expanded outreach that will increase utilization of our engineering resources. All told, our expectation is for gross margin improvement of more than ten percentage points in fiscal 2026 with further improvements in future years."

    Appointment of New Chief Operating Officer

    The Company today announced the appointment of Joseph Traut as the Company's new Chief Operating Officer effective October 1, 2025. Mr. Traut will lead the operations team, including its production and engineering activities at its facilities in Massachusetts, Maine and Texas. Prior to joining Precision Optics, he held senior operations management roles with numerous medical device companies. In connection with Mr. Traut joining the Company, in addition to his salary and benefits, the Compensation Committee and Board of the Company approved the grant of an inducement stock option to be granted on his Start Date, to purchase 60,000 shares of the Company's common stock. The Option was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of the individual's employment compensation and was granted as an inducement material to his acceptance of employment with the Company. Mr. Traut's option has an exercise price equal to the closing price of the Company's common stock as reported by the Nasdaq Capital Market on October 1, 2025. The options have a ten-year term and vest in three equal annual installments, subject to Mr. Traut's continued service with the Company through the applicable vesting dates.

    Forkey commented, "I am pleased to welcome Joe Traut as our new COO. Joe has specific expertise in building effective operations teams and transferring manufacturing operations both internationally and domestically with a history of improving business performance through operational excellence methodology and improved manufacturing efficiency. I look forward to his contributions as we continue to rapidly scale our operations."

    The following table summarizes the fourth quarter and fiscal year results for the periods ended June 30, 2025, and 2024:

      Three Months Year
      Ended June 30 Ended June 30
       2025  2024   2025  2024 
    Revenues$6,181,342 $4,716,225 $19,091,269 $19,104,350 
           
    Gross Profit 799,187  1,024,450   

    3,404,433
      

    5,797,778
     
           
    Stock Compensation Expenses 439,873  210,393   1,612,106  959,784 
    Other 1,715,356  2,170,409   7,343,618  7,562,326 
    Total Operating Expenses 2,155,229  2,380,802   8,955,724  8,522,110 
           
    Operating Income (Loss) (1,356,042) (1,356,352)  (5,551,291) (2,724,332)
           
    Net Income (Loss) (1,402,555) (1,411,106)  (5,780,246) (2,951,377)
           
    Income (Loss) per Share     
     Basic & Fully Diluted$(0.18)$(0.23) $(0.85)$(0.49)
           
          
    Weighted Average Common Shares Outstanding
     Basic & Fully Diluted 7,690,084  6,071,846   6,790,466  6,068,329 



    Conference Call Details


    Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET.

    Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or

    (412) 317-5705.

    Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/09EyQ6EXoDx.

    Replay: A teleconference replay of the call will be available for seven days, at (877) 344-7529 or (412) 317-0088, replay access code 3770234. A webcast replay will be available at https://app.webinar.net/09EyQ6EXoDx.

    About Precision Optics Corporation

    Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

    Non-GAAP Financial Measures

    Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to the aforementioned items, Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation.

    This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

    Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

    About Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, without limitation, the Company's projections for future revenue, gross margins and Adjusted EBITDA. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

    Company Contact:

    PRECISION OPTICS CORPORATION

    22 East Broadway

    Gardner, Massachusetts 01440-3338

    Telephone: 978-630-1800

    Investor Contact:

    LYTHAM PARTNERS, LLC

    Robert Blum

    Telephone: 602-889-9700

    [email protected]



     
    PRECISION OPTICS CORPORATION, INC.

    Balance Sheets at June 30, 2025 and 2024
           
      2025  2024 
    ASSETS        
    Current Assets:        
    Cash and cash equivalents $1,773,735  $405,278 
    Accounts receivable, net of allowance for credit losses of $80,192 at June 30, 2025 and $118,872 at June 30, 2024  4,336,730   3,545,491 
    Inventories, net  3,562,112   2,868,100 
    Prepaid expenses  385,390   299,364 
    Total current assets  10,057,967   7,118,233 
             
    Fixed Assets:        
    Machinery and equipment  3,385,958   3,341,194 
    Leasehold improvements  871,356   810,914 
    Furniture and fixtures  538,428   416,425 
       4,795,742   4,568,533 
    Less—Accumulated depreciation and amortization  4,261,950   4,074,960 
    Net fixed assets  533,792   493,573 
             
    Operating lease right-of-use asset  141,825   189,999 
    Patents, net  232,493   286,559 
    Goodwill  8,824,210   8,824,210 
    Total other assets  9,198,528   9,300,768 
    TOTAL ASSETS $19,790,287  $16,912,574 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current Liabilities:        
    Revolving line of credit $–  $1,000,000 
    Current portion of capital lease obligation  27,368   41,113 
    Current maturities of long-term debt  577,898   276,928 
    Accounts payable  2,909,100   1,397,313 
    Customer advances  1,821,929   1,172,350 
    Accrued compensation and other  764,004   840,662 
    Operating lease liability  50,995   178,450 
    Total current liabilities  6,151,294   4,906,816 
             
    Capital lease obligation, net of current portion  –   27,369 
    Long-term debt, net of current maturities  1,289,205   1,899,052 
    Operating lease liability, net of current portion  90,954   11,549 
    Total liabilities  7,531,453   6,844,786 
    Stockholders' Equity:        
    Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 7,714,701 shares at June 30, 2025 and 6,073,939 shares at June 30, 2024  77,147   60,739 
    Additional paid-in capital  69,152,317   61,197,433 
    Accumulated deficit  (56,970,630)  (51,190,384)
    Total stockholders' equity  12,258,834   10,067,788 
             
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $19,790,287  $16,912,574 



     
    PRECISION OPTICS CORPORATION, INC.

    Statements of Operations

    for the Years Ended June 30, 2025 and 2024
           
      2025  2024 
           
    Revenues $19,091,269  $19,104,350 
    Cost of goods sold  15,686,836   13,306,573 
             
    Gross profit  3,404,433   5,797,777 
             
    Research and development expenses, net  1,157,963   981,781 
    Selling, general and administrative expenses  7,797,761   7,540,329 
    Total operating expenses  8,955,724   8,522,110 
             
    Operating loss  (5,551,291)  (2.724,333)
             
    Other expense        
    Interest expense  (227,019)  (225,108)
             
    Loss before provision for income taxes  (5,778,310)  (2,949,441)
             
    Provision for income taxes  1,936   1,936 
             
    Net loss $(5,780,246) $(2,951,377)
             
    Loss per share:        
    Basic and fully diluted $(0.85) $(0.49)
             
    Weighted average common shares outstanding:        
    Basic and fully diluted  6,790,466   6,068,329 



     
    PRECISION OPTICS CORPORATION, INC.

    Statements of Stockholders' Equity

    for the Years Ended June 30, 2025 and 2024
                    
      Number of

    Shares
      Common

    Stock
      Additional

    Paid-in

    Capital
      Accumulated

    Deficit
      Total

    Stockholders'

    Equity
     
                    
    Balance, June 30, 2023  6,066,518  $60,665  $60,224,934  $(48,239,007) $12,046,592 
    Proceeds from exercise of stock option  4,333   43   12,746   –   12,789 
    Exercise of stock options net of 2,916 shares withheld  3,088   31   (31)  –   – 
    Stock-based compensation  –   –   959,784   –   959,784 
    Net loss  –   –   –   (2,951,377)  (2,951,377)
    Balance, June 30, 2024  6,073,939  $60,739  $61,197,433  $(51,190,384) $10,067,788 
                         
    Issuance of common stock in a registered direct offering  1,538,368   15,384   6,254,752   –   6,270,136 
    Proceeds from exercise of stock option  71,979   721   88,329   –   89,050 
    Issuance of common stock for consulting services and employees  30,415   303   151,395   –   151,698 
    Stock-based compensation  –   –   1,460,408   –   1,460,408 
    Net loss  –   –   –   (5,780,246)  (5,780,246)
    Balance, June 30, 2025  7,714,701  $77,147  $69,152,317  $(56,970,630) $12,258,834 



     
    PRECISION OPTICS CORPORATION, INC.

    Statements of Cash Flows

    For the Years Ended June 30, 2025 and 2024
           
      2025  2024 
    Cash Flows from Operating Activities:        
    Net loss $(5,780,246) $(2,951,377)
    Adjustments to reconcile net loss to net cash (used in) provided by operating activities-        
    Depreciation and amortization  212,439   212,382 
    Stock-based compensation expense  1,460,408   959,784 
    Non-cash legal expense  34,881   – 
    Non-cash interest expense  11,563   17,504 
    Non-cash operating lease expense  124   – 
    Changes in operating assets and liabilities:        
    Accounts receivable, net  (791,239)  361,916 
    Inventories  (694,012)  (91,884)
    Prepaid expenses  (86,026)  (49,683)
    Accounts payable  1,511,787   (1,034,951)
    Contract liabilities  649,579   (2,340)
    Accrued compensation and other  (76,658)  (104,363)
    Net cash used in operating activities  (3,547,400)  (2,683,012)
             
    Cash Flows from Investing Activities:        
    Reclassification/additional patent costs  (6,264)  (21,448)
    Purchases of property and equipment  (227,209)  (272,435)
    Net cash used in investing activities  (233,473)  (293,883)
             
    Cash Flows from Financing Activities:        
    Payment of capital lease obligations  (41,114)  (43,209)
    Principal payments of long-term debt  (280,440)  (513,259)
    Payment of debt issuance costs  (40,000)  – 
    (Repayments)/Borrowings on line of credit  (1,000,000)  1,000,000 
    Gross proceeds from registered direct offerings of common stock  6,270,136   – 
    Stock issued for services  151,698   – 
    Gross proceeds from exercise of stock options  89,050   12,789 
    Net cash provided by financing activities  5,149,330   456,321 
             
    Net increase (decrease) in cash and cash equivalents  1,368,457   (2,520,574)
    Cash and cash equivalents, beginning of year  405,278   2,925,852 
             
    Cash and cash equivalents, end of year $1,773,735  $405,278 
             
    Supplemental disclosure of cash flow information:        
    Cash paid during the year for income taxes $1,936  $1,936 
    Cash paid during the year for interest $216,456  $207,604 
    Operating right-of-use assets obtained in exchange for operating lease liabilities $133,650  $– 



     
    PRECISION OPTICS CORPORATION, INC.
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
    ADJUSTED EBITDA
             
      Three Months Ended   Year Ended
    June 30 June 30
      2025

      2024

      2025

      2024

    Net Income (loss) (GAAP) $(1,402,558)  $(1,411,106)  $(5,780,246)  $(2,951,376)
                    
    Stock based compensation  439,873    210,393    1,612,106    959,784 
                    
    Depreciation and amortization  60,263    55,796    212,439    212,382 
                    
    State Income Taxes  1,936    1,936    1,936    1,936 
                    
    Interest expense  44,576    52,818    227,019    225,108 
                    
    Adjusted EBITDA (non-GAAP) $(855,910)  $(1,090,163)  $(3,726,746)  $(1,552,166)
                    


    Primary Logo

    Get the next $POCI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

    GARDNER, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at https://app.web

    9/30/25 8:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Conference Call Scheduled for today, September 29, 2025, at 5:00pm ET Company introduces fiscal year 2026 Revenue and Adjusted EBITDA guidance Company appoints new Chief Operating Officer GARDNER, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year 2025 for the period ended June 30, 2025. Q4 2025 Financial Highlights (3 Months Ended June 30, 2025): Revenue was $6.2 million, a new quarterly record, compared to $4.7 million in the sa

    9/29/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    SEC Filings

    View All

    SEC Form 10-K filed by Precision Optics Corporation Inc.

    10-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    9/29/25 4:15:57 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    6/3/25 4:15:19 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Corporation Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    5/23/25 4:40:06 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

    GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

    5/8/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Second Quarter of Fiscal Year 2025 Conference Call for February 13, 2025

    GARDNER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, February 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, February 13, 2025, at 5:00 p.m. ET. Call-in Information: Inter

    2/11/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Woodward Peter H exercised 30,000 shares at a strike of $2.19 and covered exercise/tax liability with 14,536 shares (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    5/20/25 4:15:06 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Pellegrino Joseph P Jr

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    3/21/25 4:17:04 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman was granted 20,000 shares, increasing direct ownership by 16% to 142,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    3/21/25 4:15:13 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care